{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T11:10:29Z","timestamp":1772277029398,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s12325-025-03441-y","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T08:24:48Z","timestamp":1766391888000},"page":"666-687","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sensitivity Analysis of the Efficacy of Everolimus for Neurocognitive Symptoms in PTEN Hamartoma Tumor Syndrome"],"prefix":"10.1007","volume":"43","author":[{"given":"Yiran","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runqiu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddharth","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Booil","family":"Jo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Frazier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajna","family":"Filip-Dhima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charis","family":"Eng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabi","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Y.","family":"Hardan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"issue":"2","key":"3441_CR1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3257","volume":"137","author":"DM Adams","year":"2016","unstructured":"Adams DM, Trenor CC, Hammill AM, Vinks AA, Patel MN, Chaudry G, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 2016;137(2):e20153257. https:\/\/doi.org\/10.1542\/peds.2015-3257.","journal-title":"Pediatrics"},{"issue":"10056","key":"3441_CR2","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","volume":"388","author":"JA French","year":"2016","unstructured":"French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10056):2153\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(16)31419-2.","journal-title":"Lancet"},{"issue":"2","key":"3441_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/pbc.23098","volume":"57","author":"I Iacobas","year":"2011","unstructured":"Iacobas I, Burrows PE, Adams DM, Sutton VR, Hollier LH, Chintagumpala MM. Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation. Pediatr Blood Cancer. 2011;57(2):321\u20133. https:\/\/doi.org\/10.1002\/pbc.23098.","journal-title":"Pediatr Blood Cancer"},{"key":"3441_CR4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.conctc.2018.03.008","volume":"10","author":"J Twisk","year":"2018","unstructured":"Twisk J, Bosman L, Hoekstra T, Rijnhart J, Welten M, Heymans M. Different ways to estimate treatment effects in randomised controlled trials. Contemp Clin Trials Commun. 2018;10:80\u20135.","journal-title":"Contemp Clin Trials Commun."},{"issue":"12","key":"3441_CR5","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1634\/theoncologist.2019-0514","volume":"24","author":"T Komiya","year":"2019","unstructured":"Komiya T, Blumenthal GM, DeChowdhury R, Fioravanti S, Ballas MS, Morris J, et al. A pilot study of sirolimus in subjects with Cowden syndrome or other syndromes characterized by germline mutations in PTEN. Oncologist. 2019;24(12):1510-e1265. https:\/\/doi.org\/10.1634\/theoncologist.2019-0514.","journal-title":"Oncologist"},{"issue":"6","key":"3441_CR6","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/ncponc1112","volume":"5","author":"DJ Marsh","year":"2008","unstructured":"Marsh DJ, Trahair TN, Martin JL, Chee WY, Walker J, Kirk EP, et al. Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol. 2008;5(6):357\u201361. https:\/\/doi.org\/10.1038\/ncponc1112.","journal-title":"Nat Clin Pract Oncol"},{"issue":"6","key":"3441_CR7","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1007\/s00381-024-06301-2","volume":"40","author":"J Mart\u00edn-Valbuena","year":"2024","unstructured":"Mart\u00edn-Valbuena J, Gestoso-Uzal N, Justel-Rodr\u00edguez M, Isidoro-Garc\u00eda M, Marcos-Vadillo E, Lorenzo-Hern\u00e1ndez SM, et al. PTEN hamartoma tumor syndrome: clinical and genetic characterization in pediatric patients. Childs Nerv Syst. 2024;40(6):1689\u201397. https:\/\/doi.org\/10.1007\/s00381-024-06301-2.","journal-title":"Childs Nerv Syst"},{"issue":"27","key":"3441_CR8","doi-asserted-by":"publisher","first-page":"42393","DOI":"10.18632\/oncotarget.9877","volume":"7","author":"CS Matsumoto","year":"2016","unstructured":"Matsumoto CS, Almeida LO, Guimar\u00e3es DM, Martins MD, Papagerakis P, Papagerakis S, et al. PI3K-PTEN dysregulation leads to mTOR-driven upregulation of the core clock gene BMAL1 in normal and malignant epithelial cells. Oncotarget. 2016;7(27):42393\u2013407. https:\/\/doi.org\/10.18632\/oncotarget.9877.","journal-title":"Oncotarget"},{"issue":"3","key":"3441_CR9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/sj.ejhg.5200289","volume":"7","author":"MR Nelen","year":"1999","unstructured":"Nelen MR, Kremer H, Konings IB, Schoute F, van Essen AJ, Koch R, et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet. 1999;7(3):267\u201373. https:\/\/doi.org\/10.1038\/sj.ejhg.5200289.","journal-title":"Eur J Hum Genet"},{"issue":"11","key":"3441_CR10","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1038\/s41433-022-02108-0","volume":"36","author":"S Parpia","year":"2022","unstructured":"Parpia S, Morris TP, Phillips MR, Wykoff CC, Steel DH, Thabane L, et al. Sensitivity analysis in clinical trials: three criteria for a valid sensitivity analysis. Eye. 2022;36(11):2073\u20134. https:\/\/doi.org\/10.1038\/s41433-022-02108-0.","journal-title":"Eye"},{"issue":"8","key":"3441_CR11","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1038\/s41386-018-0039-3","volume":"43","author":"LC Politte","year":"2018","unstructured":"Politte LC, Scahill L, Figueroa J, McCracken JT, King B, McDougle CJ. A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures. Neuropsychopharmacology. 2018;43(8):1772\u20138. https:\/\/doi.org\/10.1038\/s41386-018-0039-3.","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"3441_CR12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/pr.2013.246","volume":"75","author":"GL Schmid","year":"2014","unstructured":"Schmid GL, K\u00e4ssner F, Uhlig HH, K\u00f6rner A, Kratzsch J, H\u00e4ndel N, et al. Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studies. Pediatr Res. 2014;75(4):527\u201334. https:\/\/doi.org\/10.1038\/pr.2013.246.","journal-title":"Pediatr Res"},{"issue":"20","key":"3441_CR13","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1093\/hmg\/ddac111","volume":"31","author":"S Srivastava","year":"2022","unstructured":"Srivastava S, Jo B, Zhang B, Frazier T, Gallagher AS, Peck F, et al. A randomized controlled trial of everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome. Hum Mol Genet. 2022;31(20):3393\u2013404. https:\/\/doi.org\/10.1093\/hmg\/ddac111.","journal-title":"Hum Mol Genet"},{"issue":"5","key":"3441_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111574","volume":"41","author":"K Tariq","year":"2022","unstructured":"Tariq K, Cullen E, Getz SA, Conching AKS, Goyette AR, Prina ML, et al. Disruption of mTORC1 rescues neuronal overgrowth and synapse function dysregulated by Pten loss. Cell Rep. 2022;41(5):111574. https:\/\/doi.org\/10.1016\/j.celrep.2022.111574.","journal-title":"Cell Rep"},{"issue":"3","key":"3441_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1542\/pedsos.2024-000349","volume":"1","author":"CL Ward","year":"2025","unstructured":"Ward CL, Wilens TE, Jin N, Turkoglu O, Skubiak T, Childress AC. Efficacy and safety of centanafadine for ADHD treatment in children: a randomized clinical trial. Pediatri Open Sci. 2025;1(3):1\u201311. https:\/\/doi.org\/10.1542\/pedsos.2024-000349","journal-title":"Pediatri Open Sci"},{"key":"3441_CR16","unstructured":"Haldeman-Englert CR, Jewett T, Mulle JG, Gambello MJ, Russo RS, Murphy MM, Burrell TL, Klaiman C, White S, Saulnier CA, Walker EF. GeneReviews\u00ae. University of Washington, Seattle. Seattle (WA). 1993. https:\/\/europepmc.org\/books\/n\/gene\/?extid=38648328&src=med. Accessed 17 Aug 2025."},{"issue":"Suppl 4","key":"3441_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.7861\/clinmed.22-4-s48","volume":"22","author":"J Zhang","year":"2022","unstructured":"Zhang J. Systematic review of mTOR inhibitor treatment, biomarkers and prophylaxis for tuberous sclerosis complex-associated seizures. Clin Med. 2022;22(Suppl 4):48\u20139. https:\/\/doi.org\/10.7861\/clinmed.22-4-s48.","journal-title":"Clin Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03441-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03441-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03441-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:03:33Z","timestamp":1771268613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03441-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3441"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03441-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Thomas Frazier has received funding or research support from, acted as a consultant to, received travel support from, and\/or received a speaker\u2019s honorarium from the PTEN Research Foundation, SYNGAP Research Fund, Malan Syndrome Foundation, ADNP Kids Research Foundation, Quadrant Biosciences, Autism Speaks, Impel NeuroPharma, F. Hoffmann-La Roche AG Pharmaceuticals, the Cole Family Research Fund, Simons Foundation, Ingalls Foundation, Forest Laboratories, Ecoeos, IntegraGen, Kugona LLC, Shire Development, Bristol-Myers Squibb, Roche Pharma, MaraBio, Scioto Biosciences, Linus Biotechnology, National Institutes of Health, and the Brain and Behavior Research Foundation, has equity options in Quadrant Biosciences\/Autism Analytica, MaraBio, has an investor stake in Autism EYES LLC, is a co-owner of iSCAN-R and AI-Measures, and is employed by CentralReach. Yiran Liu is affiliated with the Data and Decision Sciences program at Emory University following the completion of this work. Runqiu Wang, Siddharth Srivastava, Booil Jo, Rajna Filip-Dhima, Charis Eng, Rabi Hanna, Mustafa Sahin, Antonio Y. Hardan, and Bo Zhang declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The parent trial (ClinicalTrials.gov identifier: NCT02991807) was approved by the Institutional Review Boards of Boston Children\u2019s Hospital, Stanford University, and the Cleveland Clinic. Written informed consent (and assent where applicable) was obtained from all participants or their legal guardians prior to enrollment. This secondary analysis utilized only de-identified trial data and did not involve any new research with human participants or animals by the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}